References
CONSORT flow diagram depicting the progression of participants through the study. Ten eligible participants were randomly assigned according to a computer-generated allocation schedule to 1 of 2 treatment sequences: hydroxychloroquine sulfate (HCQS) the first study visit and placebo the second study visit or the placebo the first study visit and HCQS the second study visit. All randomized participants completed the study.Schematic overview of the study design. First, an intravenous dwelling line was positioned for blood sample collection. A baseline blood sample was taken at timepoint −10. At timepoint 0, two tablets of PlaquenilHydroxychloroquine sulfate tends to reduce hunger ratings 50–60 min after ingestion. Effect of placebo and hydroxychloroquine sulfate (HCQS, 400 mg) on (Hydroxychloroquine sulfate reduces acyl-ghrelin plasma concentrations 40–50 min after ingestion. Effect of placebo and hydroxychloroquine sulfate (HCQS, 400 mg) on (Hydroxychloroquine sulfate does not appear to influence plasma insulin concentrations or glucose levels. Effect of placebo and hydroxychloroquine sulfate (HCQS, 400 mg) on (Hydroxychloroquine sulfate (400 mg) does not cause any undesirable symptoms. Symptom scores with an absolute value above 10 out of 100 mm VAS were considered in this study. The surface severity (area under the curve) above the cut-off is presented for both the fasted and fed states in the table. Data are presented as IQR (mm).